On Oct 31, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $10 to $26.
BofA Securities analyst Tazeen Ahmad maintains with a sell rating.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $10.
Needham analyst Ami Fadia maintains with a hold rating.
Stifel analyst Paul Matteis maintains with a hold rating, and sets the target price at $10.
Piper Sandler analyst Yasmeen Rahimi maintains with a buy rating, and adjusts the target price from $100 to $26.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics reported third-quarter results, including total revenue of $11.9M, operating expenses of $113.1M, and cash reserves of $569.2M, which are projected to sustain the company into 2026. The company experienced a setback as SAGE-718 did not meet the expected outcomes in the Phase 2 LIGHTWAVE study for AD-MCI patients, leading to a strategic shift to focus on Zurzuvae and the exploration of dalzanemdor for HD-MCI, with Phase 2 DIMENSION results anticipated by the end of 2024. Commentary from related industry players regarding their third-quarter updates in 2024 is also expected.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
